Literature DB >> 6091473

Combined ceftriaxone and surgical therapy for osteomyelitis in hospital and outpatient settings.

L J Eron, R I Goldenberg, D M Poretz.   

Abstract

The combined medical-surgical approach to therapy for osteomyelitis requires patients to receive intravenous antibiotics three to six times daily for 4 to 6 weeks after initial surgical debridement. The greatly extended half-life of the new cephalosporin, ceftriaxone (6 to 8 hours), enabled its intravenous administration once or twice daily to 76 patients for the treatment of osteomyelitis. Cure or improvement was noted in 66 of the 76 patients (87 percent). Most of the failures occurred in the group of patients with osteomyelitis complicated by vascular insufficiency. The once or twice daily dosing possible with ceftriaxone was particularly advantageous for permitting highly cost-effective at home therapy for 42 of the 76 patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6091473

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  5 in total

Review 1.  Discovery and development of new antimicrobial agents.

Authors:  T D Gootz
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

Review 2.  Parenteral cephalosporin therapy in ambulatory care: advantages and disadvantages.

Authors:  S Esposito
Journal:  Drugs       Date:  2000       Impact factor: 9.546

Review 3.  Ambulatory use of parenteral antibacterials: contemporary perspectives.

Authors:  J E Leggett
Journal:  Drugs       Date:  2000       Impact factor: 9.546

Review 4.  Outpatient parenteral antimicrobial therapy with ceftriaxone, a review.

Authors:  Christopher J A Duncan; David A Barr; R Andrew Seaton
Journal:  Int J Clin Pharm       Date:  2012-04-17

5.  Outpatient parenteral antimicrobial therapy practices among adult infectious disease physicians.

Authors:  Michael A Lane; Jonas Marschall; Susan E Beekmann; Philip M Polgreen; Ritu Banerjee; Adam L Hersh; Hilary M Babcock
Journal:  Infect Control Hosp Epidemiol       Date:  2014-05-09       Impact factor: 3.254

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.